{"entity":{"id":"paper-beamion-lung-1-zongertinib-nejm-2025","kind":"paper","name":"Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer","aka":[],"tldr":"The oral HER2-selective kinase inhibitor zongertinib shrank tumours in about seven in ten patients with previously treated HER2-mutant lung cancer with little of the diarrhoea and rash that plagued earlier HER2 pills, becoming the first oral drug approved for this driver.","summary":"Phase 1a/1b study; the primary cohort treated 75 patients with previously treated HER2 tyrosine kinase domain-mutant advanced non-small-cell lung cancer with zongertinib 120 mg daily.\n\nObjective response was 71 percent with a median progression-free survival of 12.4 months, intracranial activity in patients with brain metastases, and mainly low-grade diarrhoea and rash; a separate cohort showed activity after prior trastuzumab deruxtecan.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2025","url":"https://doi.org/10.1056/NEJMoa2503704"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40293180/"}],"tags":[],"related":[],"cancers":["her2-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zongertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["beamion-lung-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2025,"doi":"10.1056/NEJMoa2503704","pmid":"40293180","authors":"Heymach JV, Ruiter G, Ahn MJ, et al.","paperType":"observational","findings":["Objective response 71 percent.","Median progression-free survival 12.4 months."],"whatItMeans":"Zongertinib gives HER2-mutant lung cancer an oral targeted option with brain activity, used after platinum chemotherapy and increasingly before or after trastuzumab deruxtecan.","caveats":["Single-arm phase 1 data; first-line trials against chemo-immunotherapy are ongoing."],"changedPractice":true,"participants":75},"route":"/key-papers/paper-beamion-lung-1-zongertinib-nejm-2025/","neighbours":{"cancer":[{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"}],"drug":[{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/"}],"trial":[{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}